STRIVE S-217622 Drug Interaction Screening Tool (STRIVE DDI Screener)
This STRIVE DDI Screener is a research tool for use ONLY in the context of
the STRIVE S-217622 (ensitrelvir) clinical trial. This tool reflects the drug
interaction data regarding S-217622 currently available to the study
sponsor and protocol team, and may be updated. This tool is not intended
to direct clinical management. The information from this tool may be
provided to clinical teams to help inform their decisions. Decisions on
whether to continue, start, or stop a medication should be made by the
clinical care team in consultation with a clinical pharmacist at their
clinical site. Study participants must be informed during consenting
process, and during study conduct, about the possibility of drug
interactions and the potential for medication changes
Drug (generic):
Drug-drug interactions (DDI) with S-217622 should be checked for all concomitant medications prior to enrollment and before initiating a new medication during study (through Day 15). Please use the search function on this STRIVE DDI Screener webpage and follow the specific guidance provided.
Browser compatibility: Google Chrome (recommended), Microsoft Edge (does not work at VA medical centers), Safari(Mac)
For general comments to study team on DDI screener click HERE
To request that a medication be added to the DDI screener click HERE
STRIVE S-217622 Broad Recommendations for Certain Drug Classes
Drug Class
STRIVE Recommendation
Comments
Insulins (all types)
Permitted
Continue to enter each medication from these classes into the STRIVE DDI screener and if they are listed, follow the additional guidance provided.
Probiotics
Nutritional Supplements
Vitamins
Vaccines
Agents administered for imaging procedures (i.e. contrast)
Topical/Dermatologic Agents
Inhaled Agents
Herbals
Prohibited with some exceptions
Herbal products are recommended to be stopped within 12 hours prior to the first S-217622/placebo dose, held during study drug administration, and may resume 24 hours after the administration of last dose of study.
Exceptions include: St. John's Wort, Red Rice Yeast, Echinacea, Ginkgo biloba (please see specific guidance for each in the DDI screener)
Prohibited drugs with long half-lives
Concomitant drugs with a long half-life can still interact with S-217622 even after the concomitant drug is discontinued. When evaluating DDI, all medications taken by the patient within the past 14 days (including those recently discontinued) should be entered into the STRIVE DDI Screener for guidance. In addition, ask the patient if they have received any of the drugs in the table below recently (during the washout period listed below), as these drugs require a longer washout period than 14 days.
Drugs with long washout period (≥ 15 days)
Drug Name
Washout period needed prior to enrollment (days)
Potential Clinical Impact
Amiodarone
180
Prolonged exposure to amiodarone
Anacetrapib
24
Prolonged exposure to anacetrapib
Apalutamide
15
Decreased S-217622 exposure
Dutasteride
180
Prolonged exposure to dutasteride
Gilteritinib
24
Prolonged exposure to gilteritinib
Halofantrine
24
Prolonged exposure to halofantrine
Haloperidol decanoate
60
Prolonged exposure to haloperidol decanoate
Ivosidenib
27
Decreased S-217622 exposure and prolonged exposure to ivosidenib